265 related articles for article (PubMed ID: 35908365)
1. Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
Chow JCH; Lee AWM; Wong CHL; Ng WT; Liu Z; Tay JK; Loh KS; Pace-Asciak P; Cohen O; Corry J; Rodrigo JP; Tsang RKY; Lopez F; Saba NF; de Bree R; Ferlito A
Oral Oncol; 2022 Oct; 133():106031. PubMed ID: 35908365
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
3. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
4. The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma.
Tay JK; Chan SH; Lim CM; Siow CH; Goh HL; Loh KS
Otolaryngol Head Neck Surg; 2016 Aug; 155(2):274-80. PubMed ID: 27143706
[TBL] [Abstract][Full Text] [Related]
5. Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs.
Chen GH; Liu Z; Yu KJ; Coghill AE; Chen XX; Xie SH; Lin DF; Huang QH; Lu YQ; Ling W; Lin CY; Lu ZJ; Fan YY; Tang LQ; Sampson JN; Li H; King AD; Middeldorp JM; Hildesheim A; Cao SM
Clin Chem; 2022 Jul; 68(7):953-962. PubMed ID: 35325087
[TBL] [Abstract][Full Text] [Related]
6. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
7. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
[TBL] [Abstract][Full Text] [Related]
8. A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.
Tay JK; Siow CH; Goh HL; Lim CM; Hsu PP; Chan SH; Loh KS
Int J Cancer; 2020 May; 146(10):2923-2931. PubMed ID: 31705522
[TBL] [Abstract][Full Text] [Related]
9. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
10. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
Yu KJ; Hsu WL; Pfeiffer RM; Chiang CJ; Wang CP; Lou PJ; Cheng YJ; Gravitt P; Diehl SR; Goldstein AM; Chen CJ; Hildesheim A
Clin Cancer Res; 2011 Apr; 17(7):1906-14. PubMed ID: 21447725
[TBL] [Abstract][Full Text] [Related]
11. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
[TBL] [Abstract][Full Text] [Related]
12. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
[TBL] [Abstract][Full Text] [Related]
13. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
[TBL] [Abstract][Full Text] [Related]
14. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
16. Cigarette smoking increases the risk of nasopharyngeal carcinoma through the elevated level of IgA antibody against Epstein-Barr virus capsid antigen: A mediation analysis.
Hsu WL; Chien YC; Huang YT; Yu KJ; Ko JY; Lin CY; Tsou YA; Leu YS; Liao LJ; Chang YL; Su JY; Liu Z; Wang CP; Terng SD; Hua CH; Lee JC; Yang TL; Kate Hsiao CH; Wu MS; Tsai MH; Liu MJ; Lou PJ; Hildesheim A; Chen CJ;
Cancer Med; 2020 Mar; 9(5):1867-1876. PubMed ID: 31925935
[TBL] [Abstract][Full Text] [Related]
17. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
[TBL] [Abstract][Full Text] [Related]
19. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
[TBL] [Abstract][Full Text] [Related]
20. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
Luo YL; Chen H; Peng SG; Lin JH; Huang PY
Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]